key: cord-0901439-p8rffipn
authors: Siegel, Arthur J.
title: Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic
date: 2021-04-19
journal: Am J Med
DOI: 10.1016/j.amjmed.2020.11.008
sha: 5cbd3df744b4fb8b7b2f7df383b0c64399ae4c1a
doc_id: 901439
cord_uid: p8rffipn

nan

To the Editor:

The meta-regression analysis by Nudy et al 1 demonstrates a benefit from aspirin use for primary cardiovascular prevention, corroborating the final report on aspirin in the Physicians' Health Study. 2 Based on a consensus that "exercise is known to acutely, albeit transiently, increase the relative risk for sudden cardiac death and acute myocardial infarction," 3 low-dose aspirin has been proposed to mitigate the increasing frequency of such events resulting from coronary atherosclerosis in middle-aged male recreational athletes. 4 Exercise-induced troponin I elevations predict cardiovascular events and higher mortality in a cohort of older long-distance walkers. 5 As a randomized trial of aspirin in runners lacks feasibility because of the low incidence of index events, athletes with ancillary indices of increased risk are most likely to benefit from such use. 6, 7 Aspirin use for primary prevention warrants consideration in other clinical conditions which generate a systemic inflammatory response. The cytokine storm associated with the coronavirus disease 2019 (COVID-19) infection is a case in point, accounting in part for the excess cardiovascular morbidity and mortality observed during prior viral epidemics. [8] [9] [10] Manifestations include the correlation of C-reactive protein levels with cardiac troponins and hypercoagulability with elevated concentrations of D-dimer, which findings may be attenuated by aspirin's anti-inflammatory and antithrombotic effects. Improvement in clinical outcomes including decreased mortality with aspirin in hospitalized patients with coronavirus disease 2019 infection justifies a sufficiently powered randomized controlled primary prevention trial. 11, 12 Pending the availability of such data, why not exploit the cardioprotective benefit of aspirin by enhancing its use for primary cardiovascular prevention during this pandemic? Arthur J. Siegel, MD a,b,c a Division of General Internal Medicine, Massachusetts General Hospital, Boston, Mass

Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: a meta-regression analysis

Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study

Exercise-related acute cardiovascular events and potential deleterious adaptations following long-term exercise

Pheidippides redux: reducing the acute cardiac risk during marathon running

Exerciseinduced cardiac troponin I increase and incident mortality and cardiovascular events

Aspirin to prevent sudden cardiac death in athletes with high coronary artery calcium scores

Aspirin to reduce risk for sudden cardiac death in athletes with elevated C-reactive protein levels: preventing exertional cardiac arrest in high-risk athletes

Coronavirus disease 2019 (COVID-19) and cardiovascular disease

Cardiovascular implications of fatal outcomes of patients with coronavirus disease

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease deaths: results from 8 years of autopsies in 34,892 subjects

Aspirin use for enhanced primary cardiovascular prevention during the coronavirus-19 pandemic

Aspirin use is associated with the decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with a COVID-19